X4 Pharmaceuticals, Inc (XFOR) stock intrinsic value fair value estimate & owner earnings analysis

X4 Pharmaceuticals is a commercial-stage biopharmaceutical company. Its product, XOLREMDI (mavorixafor), was approved by the FDA on April 29, 2024 and launched in the second quarter of 2024. Through the end of 2025 it had generated only $9.1 million of cumulative net product revenue. In 2025, total revenue was $35.1 million, but $27.6 million of that was license revenue from an exclusive licensing and supply agreement with Norgine, not product sales. What the business earns today: for 2025 the company reported a net loss of $79.2 million and used $85.6 million of cash in operations. After deducting stock compensation ($4.3 million), owner earnings were roughly negative $89 million (about negative $2.11 per share). Owner earnings have been negative in every year we measured (2020 to 2025), between roughly negative $65 million and negative $143 million a year. The 2025 loss was smaller than 2024 partly because of the one-time-style license revenue and a September 2025 restructuring, not because product sales cover costs. Per-share figures across years are not directly comparable because the share count has changed through reverse splits and new issuance. How we value it: we only credit earning power that is secured or proven. Nothing in the filings shows product revenue approaching the company's operating costs, and no contract or track record we can point to turns owner earnings positive. Growth in XOLREMDI sales, further license payments and any pipeline success are hoped-for rather than in the bag, so we leave them out. Following our approach of not netting the balance sheet against a case value, the bear, base and bull cases are each worth $0 per share. This is a statement about the absence of evidenced earning power, not a claim that the company has no assets: at December 31, 2025 it held $253.0 million of cash, cash equivalents and short-term marketable securities against $75.0 million borrowed under a term loan with Hercules. Management states this cash should fund operations for at least the next 12 months and, together with its cost reductions, into 2028, subject to loan covenants. The loan requires cash above 20% of borrowings and trailing six-month net product revenue of at least 55% of a board-approved forecast; a covenant breach would let the lender accelerate repayment. The risk factors also warn that substantial doubt about continuing as a going concern could be raised again if the company needs more capital and cannot raise it. Bear case: continued cash burn at or near recent levels, product revenue that does not scale, covenant pressure and further equity dilution; value $0. Base case: the same, because no evidenced driver produces positive owner earnings; value $0. Bull case: even if XOLREMDI sales grow and cost cuts take hold, we cannot point to a signed contract or record that produces positive owner earnings, so it is also $0. What would make this estimate wrong: rapid, sustained growth in XOLREMDI net product revenue, or additional licensing payments, sufficient to cover operating costs. We would revisit the estimate if quarterly results show owner earnings turning positive. On current evidence there is no positive margin-of-safety price.